Mao Inhibitors + Entrectinib Interaction
Moderateinteraction on record
Description
Coadministration increases entrectinib plasma concentrations, which could increase frequency or severity of adverse reactions. Dose reduction required for patients ≥2 years; avoid in patients <2 years.
Mechanism
CYP3A inhibition
Source: NLP:entrectinib